Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy

Background—Doxorubicin causes a chronic cardiomyopathy of unknown pathogenesis. We investigated whether acquired defects in mitochondrial DNA (mtDNA) and interconnected respiratory chain dysfunction may represent a molecular mechanism for its late onset. Methods and Results—Rats were treated weekly with intravenous doxorubicin (1 mg/kg) for 7 weeks, starting at 11 weeks of age (group B). Controls received saline. Group C received doxorubicin identically to group B, but the course was started at 41 weeks of age. All rats were killed at week 48. Doxorubicin was also injected once, either 6 days (group D) or 2 hours (group E) before euthanasia. Heart and skeletal muscle were examined. Only group B rats developed a significant clinical, macroscopic, histological, and ultrastructural cardiomyopathy. Group B hearts had the lowest cytochrome c oxidase (COX) activity (24% of controls; P =0.003), the highest citrate synthase activity (135% of controls; P =0.005), and the highest production of superoxide. In group B, the respiratory subunit COXI, which is encoded by mtDNA, was reduced (P <0.001), as was mtDNA (49% of controls, P <0.001). Group C hearts differed from group B in their lower cardiomyopathy score (P =0.006), higher COX activity (P =0.02), and higher mtDNA content (P =0.04). Group B and to a lesser extent group C hearts contained deleted mtDNA. There was no detectable mitochondrial toxicity in group D and E hearts or in skeletal muscle. Conclusions—In doxorubicin cardiomyopathy, mtDNA alterations, superoxide, and respiratory chain dysfunction accumulate long-term in the absence of the drug and are associated with a late onset.

[1]  S. Dimauro,et al.  Fatal infantile mitochondrial myopathy and renal dysfunction due to cytochrome-c-oxidase deficiency. , 1980, Neurology.

[2]  M. Cheang,et al.  Comparison of adriamycin uptake in chick embryo heart and liver cells an murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity. , 1986, Cancer research.

[3]  H. Nohl.  Demonstration of the existence of an organo-specific NADH dehydrogenase in heart mitochondria. , 1987, European journal of biochemistry.

[4]  S. Dimauro,et al.  A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. , 1989, Science.

[5]  R. Brasseur,et al.  Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. , 1990, Biophysical chemistry.

[6]  E. Holme,et al.  Progressive Increase of the Mutated Mitochondrial DNA Fraction in Kearns-Sayre Syndrome , 1990, Pediatric Research.

[7]  V. Tiranti,et al.  Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNALeu(UUR) , 1991, The Lancet.

[8]  D. Wallace,et al.  Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease. , 1991, JAMA.

[9]  A. Benson,et al.  Biochemical determinants of Adriamycin toxicity in mouse liver, heart and intestine. , 1992, Biochemical pharmacology.

[10]  H. Toshima,et al.  A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. , 1993, Biochemical and biophysical research communications.

[11]  O. C. Stine,et al.  Detection and quantitation by competitive PCR of an age-associated increase in a 4.8-kb deletion in rat mitochondrial DNA. , 1994, Mutation research.

[12]  C. Epstein,et al.  Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase , 1995, Nature Genetics.

[13]  R. Capaldi,et al.  Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. , 1995, Methods in enzymology.

[14]  M. Iatropoulos,et al.  Long-Lasting Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in Rats , 1996, Toxicologic pathology.

[15]  B. Davidson,et al.  Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. , 1998, Circulation research.

[16]  C. Palmeira,et al.  Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. , 1999, Biochimica et biophysica acta.

[17]  M. Runge,et al.  Doxorubicin-Induced Cardiomyopathy , 2000 .

[18]  A. Capucci,et al.  Skeletal muscle training in chronic heart failure. , 2001, Acta physiologica Scandinavica.

[19]  S. Staszewski,et al.  Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor‐Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[20]  J. Robert,et al.  Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. , 2002, Biochemical pharmacology.

[21]  C. Leeuwenburgh,et al.  Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. , 2002, Cancer research.